Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study
Introduction Effectiveness and respiratory adverse events following coronavirus disease-2019 (COVID-19) vaccines have not been well investigated in Chinese patients with chronic obstructive pulmonary disease (COPD) and asthma. Methods Using electronic health care records in Hong Kong, we included ad...
Gespeichert in:
| Veröffentlicht in: | Drug safety 2024-02, Vol.47 (2), p.135-146 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 146 |
|---|---|
| container_issue | 2 |
| container_start_page | 135 |
| container_title | Drug safety |
| container_volume | 47 |
| creator | Qin, Simon Xiwen Cheng, Franco Wing Tak Kwok, Wang Chun Fung, Lydia W. Y. Ma, Tian Tian Yiu, Hei Hang Edmund Bloom, Chloe McDonald, Christine F. Cheung, Ching-Lung Lai, Francisco Tsz Tsun Chui, Celine Sze Ling Li, Xue Wong, Carlos King Ho Wan, Eric Yuk Fai Wong, Ian Chi Kei Chan, Esther Wai Yin |
| description | Introduction
Effectiveness and respiratory adverse events following coronavirus disease-2019 (COVID-19) vaccines have not been well investigated in Chinese patients with chronic obstructive pulmonary disease (COPD) and asthma.
Methods
Using electronic health care records in Hong Kong, we included adults with COPD or asthma or both and hospitalised for severe respiratory exacerbation in a self-controlled case series (SCCS) study between 23/02/2021 and 30/11/2022. Conditional Poisson regression models were used to estimate the incidence of outcomes within exposure periods (28 days after each dose) compared with baseline periods. Cox proportional hazard models evaluated vaccine effectiveness (VE) against COVID-related mortality, hospitalisation, and severe complications, including admission to intensive care units or ventilatory support. The VE assessment was based on vaccine types and the number of doses.
Results
In the SCCS, 343 CoronaVac recipients and 212 BNT162b2 recipients were included. No increased risk of outcomes was observed within the exposure periods. In the cohort study, 108,423 and 83,323 patients received ≥ 2 doses of CoronaVac and BNT162b2, respectively. The VE (95% CI) against COVID-related mortality, hospitalisation, and severe complications after two-dose CoronaVac was 77% (74–80%), 18% (6–23%), and 29% (12–43%), respectively, while for the two-dose regimen of BNT162b2, it was 92% (91–94%), 33% (30–37%), and 57% (45–66%), respectively. Higher VE against COVID-related mortality, hospitalisation, and severe complications was found for the three-dose regimen of CoronaVac (94%, 40%, and 71%) and BNT162b2 (98%, 65%, and 83%). Administering a fourth dose of either vaccine showed additional reductions in COVID-related outcomes.
Conclusions
Among people with COPD and asthma, the COVID-19 vaccines CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential and should be encouraged to protect this vulnerable population in future epidemic waves. |
| doi_str_mv | 10.1007/s40264-023-01364-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10821837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2919858504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-2546d7dd56b9ba01ae95146529c594afa6d7842e470edc9433008c7859c10943</originalsourceid><addsrcrecordid>eNp9Ud1u0zAUthCIlcELcIEscR1mO3Zic4NK122VJlaNabeWmzitpzTubKdT34ZH3Uk7NnbDlY_1_R2dD6HPlHyjhJQnkRNW8IywPCM0h6l8g0aUliqjirO3aEQo5ZlQtDhCH2K8I4RIVsj36CiXRApByAj9mTaNrZLb2s7GiE1X42sbNy6Y5MMOj-utDdHiKeAp4jPftv7BdUs868ygMsnWe9H6-tcYT65uZ6cQjm9NVTkwxK7Dc5PcXvzg0goo89O9YBzTam2-Y1CtBqrFc7_pWyD7LvtpIvj-Tn29-4jeNaaN9tPTe4xuzqY3k4vs8up8NhlfZhUvRcqY4EVd1rUoFmphCDVWCcoLwVQlFDeNAVRyZnlJbF0pnudwjKqUQlWUwPcY_TjYbvrFGhiwcTCt3gS3NmGnvXH6NdK5lV76raZwUyrzEhy-PjkEf9_bmPSd70MHO2umqJJCCjLksAOrCj7GYJvnCEr00Ko-tKqhVb1vVQ_WX_5d7lnyt0Yg5AdCBKhb2vCS_R_bR4R2rf0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919858504</pqid></control><display><type>article</type><title>Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Qin, Simon Xiwen ; Cheng, Franco Wing Tak ; Kwok, Wang Chun ; Fung, Lydia W. Y. ; Ma, Tian Tian ; Yiu, Hei Hang Edmund ; Bloom, Chloe ; McDonald, Christine F. ; Cheung, Ching-Lung ; Lai, Francisco Tsz Tsun ; Chui, Celine Sze Ling ; Li, Xue ; Wong, Carlos King Ho ; Wan, Eric Yuk Fai ; Wong, Ian Chi Kei ; Chan, Esther Wai Yin</creator><creatorcontrib>Qin, Simon Xiwen ; Cheng, Franco Wing Tak ; Kwok, Wang Chun ; Fung, Lydia W. Y. ; Ma, Tian Tian ; Yiu, Hei Hang Edmund ; Bloom, Chloe ; McDonald, Christine F. ; Cheung, Ching-Lung ; Lai, Francisco Tsz Tsun ; Chui, Celine Sze Ling ; Li, Xue ; Wong, Carlos King Ho ; Wan, Eric Yuk Fai ; Wong, Ian Chi Kei ; Chan, Esther Wai Yin</creatorcontrib><description>Introduction
Effectiveness and respiratory adverse events following coronavirus disease-2019 (COVID-19) vaccines have not been well investigated in Chinese patients with chronic obstructive pulmonary disease (COPD) and asthma.
Methods
Using electronic health care records in Hong Kong, we included adults with COPD or asthma or both and hospitalised for severe respiratory exacerbation in a self-controlled case series (SCCS) study between 23/02/2021 and 30/11/2022. Conditional Poisson regression models were used to estimate the incidence of outcomes within exposure periods (28 days after each dose) compared with baseline periods. Cox proportional hazard models evaluated vaccine effectiveness (VE) against COVID-related mortality, hospitalisation, and severe complications, including admission to intensive care units or ventilatory support. The VE assessment was based on vaccine types and the number of doses.
Results
In the SCCS, 343 CoronaVac recipients and 212 BNT162b2 recipients were included. No increased risk of outcomes was observed within the exposure periods. In the cohort study, 108,423 and 83,323 patients received ≥ 2 doses of CoronaVac and BNT162b2, respectively. The VE (95% CI) against COVID-related mortality, hospitalisation, and severe complications after two-dose CoronaVac was 77% (74–80%), 18% (6–23%), and 29% (12–43%), respectively, while for the two-dose regimen of BNT162b2, it was 92% (91–94%), 33% (30–37%), and 57% (45–66%), respectively. Higher VE against COVID-related mortality, hospitalisation, and severe complications was found for the three-dose regimen of CoronaVac (94%, 40%, and 71%) and BNT162b2 (98%, 65%, and 83%). Administering a fourth dose of either vaccine showed additional reductions in COVID-related outcomes.
Conclusions
Among people with COPD and asthma, the COVID-19 vaccines CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential and should be encouraged to protect this vulnerable population in future epidemic waves.</description><identifier>ISSN: 0114-5916</identifier><identifier>EISSN: 1179-1942</identifier><identifier>DOI: 10.1007/s40264-023-01364-7</identifier><identifier>PMID: 38085500</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Adverse events ; Asthma ; BNT162 Vaccine ; Chronic obstructive pulmonary disease ; Cohort Studies ; Complications ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; Drug Safety and Pharmacovigilance ; Effectiveness ; Electronic health records ; Hong Kong - epidemiology ; Hospitals ; Humans ; Immunization ; Intensive care units ; Lung diseases ; Medicine ; Medicine & Public Health ; Mortality ; mRNA ; Obstructive lung disease ; Original ; Original Research Article ; Pharmacology/Toxicology ; Population studies ; Population-based studies ; Pulmonary Disease, Chronic Obstructive ; Regression analysis ; Regression models ; Statistical models ; Vaccine efficacy ; Vaccines ; Viral diseases</subject><ispartof>Drug safety, 2024-02, Vol.47 (2), p.135-146</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>Copyright Springer Nature B.V. Feb 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-2546d7dd56b9ba01ae95146529c594afa6d7842e470edc9433008c7859c10943</citedby><cites>FETCH-LOGICAL-c475t-2546d7dd56b9ba01ae95146529c594afa6d7842e470edc9433008c7859c10943</cites><orcidid>0000-0002-7602-9470</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40264-023-01364-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40264-023-01364-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38085500$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qin, Simon Xiwen</creatorcontrib><creatorcontrib>Cheng, Franco Wing Tak</creatorcontrib><creatorcontrib>Kwok, Wang Chun</creatorcontrib><creatorcontrib>Fung, Lydia W. Y.</creatorcontrib><creatorcontrib>Ma, Tian Tian</creatorcontrib><creatorcontrib>Yiu, Hei Hang Edmund</creatorcontrib><creatorcontrib>Bloom, Chloe</creatorcontrib><creatorcontrib>McDonald, Christine F.</creatorcontrib><creatorcontrib>Cheung, Ching-Lung</creatorcontrib><creatorcontrib>Lai, Francisco Tsz Tsun</creatorcontrib><creatorcontrib>Chui, Celine Sze Ling</creatorcontrib><creatorcontrib>Li, Xue</creatorcontrib><creatorcontrib>Wong, Carlos King Ho</creatorcontrib><creatorcontrib>Wan, Eric Yuk Fai</creatorcontrib><creatorcontrib>Wong, Ian Chi Kei</creatorcontrib><creatorcontrib>Chan, Esther Wai Yin</creatorcontrib><title>Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study</title><title>Drug safety</title><addtitle>Drug Saf</addtitle><addtitle>Drug Saf</addtitle><description>Introduction
Effectiveness and respiratory adverse events following coronavirus disease-2019 (COVID-19) vaccines have not been well investigated in Chinese patients with chronic obstructive pulmonary disease (COPD) and asthma.
Methods
Using electronic health care records in Hong Kong, we included adults with COPD or asthma or both and hospitalised for severe respiratory exacerbation in a self-controlled case series (SCCS) study between 23/02/2021 and 30/11/2022. Conditional Poisson regression models were used to estimate the incidence of outcomes within exposure periods (28 days after each dose) compared with baseline periods. Cox proportional hazard models evaluated vaccine effectiveness (VE) against COVID-related mortality, hospitalisation, and severe complications, including admission to intensive care units or ventilatory support. The VE assessment was based on vaccine types and the number of doses.
Results
In the SCCS, 343 CoronaVac recipients and 212 BNT162b2 recipients were included. No increased risk of outcomes was observed within the exposure periods. In the cohort study, 108,423 and 83,323 patients received ≥ 2 doses of CoronaVac and BNT162b2, respectively. The VE (95% CI) against COVID-related mortality, hospitalisation, and severe complications after two-dose CoronaVac was 77% (74–80%), 18% (6–23%), and 29% (12–43%), respectively, while for the two-dose regimen of BNT162b2, it was 92% (91–94%), 33% (30–37%), and 57% (45–66%), respectively. Higher VE against COVID-related mortality, hospitalisation, and severe complications was found for the three-dose regimen of CoronaVac (94%, 40%, and 71%) and BNT162b2 (98%, 65%, and 83%). Administering a fourth dose of either vaccine showed additional reductions in COVID-related outcomes.
Conclusions
Among people with COPD and asthma, the COVID-19 vaccines CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential and should be encouraged to protect this vulnerable population in future epidemic waves.</description><subject>Adult</subject><subject>Adverse events</subject><subject>Asthma</subject><subject>BNT162 Vaccine</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Cohort Studies</subject><subject>Complications</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Effectiveness</subject><subject>Electronic health records</subject><subject>Hong Kong - epidemiology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunization</subject><subject>Intensive care units</subject><subject>Lung diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>mRNA</subject><subject>Obstructive lung disease</subject><subject>Original</subject><subject>Original Research Article</subject><subject>Pharmacology/Toxicology</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Pulmonary Disease, Chronic Obstructive</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Statistical models</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>0114-5916</issn><issn>1179-1942</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9Ud1u0zAUthCIlcELcIEscR1mO3Zic4NK122VJlaNabeWmzitpzTubKdT34ZH3Uk7NnbDlY_1_R2dD6HPlHyjhJQnkRNW8IywPCM0h6l8g0aUliqjirO3aEQo5ZlQtDhCH2K8I4RIVsj36CiXRApByAj9mTaNrZLb2s7GiE1X42sbNy6Y5MMOj-utDdHiKeAp4jPftv7BdUs868ygMsnWe9H6-tcYT65uZ6cQjm9NVTkwxK7Dc5PcXvzg0goo89O9YBzTam2-Y1CtBqrFc7_pWyD7LvtpIvj-Tn29-4jeNaaN9tPTe4xuzqY3k4vs8up8NhlfZhUvRcqY4EVd1rUoFmphCDVWCcoLwVQlFDeNAVRyZnlJbF0pnudwjKqUQlWUwPcY_TjYbvrFGhiwcTCt3gS3NmGnvXH6NdK5lV76raZwUyrzEhy-PjkEf9_bmPSd70MHO2umqJJCCjLksAOrCj7GYJvnCEr00Ko-tKqhVb1vVQ_WX_5d7lnyt0Yg5AdCBKhb2vCS_R_bR4R2rf0</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Qin, Simon Xiwen</creator><creator>Cheng, Franco Wing Tak</creator><creator>Kwok, Wang Chun</creator><creator>Fung, Lydia W. Y.</creator><creator>Ma, Tian Tian</creator><creator>Yiu, Hei Hang Edmund</creator><creator>Bloom, Chloe</creator><creator>McDonald, Christine F.</creator><creator>Cheung, Ching-Lung</creator><creator>Lai, Francisco Tsz Tsun</creator><creator>Chui, Celine Sze Ling</creator><creator>Li, Xue</creator><creator>Wong, Carlos King Ho</creator><creator>Wan, Eric Yuk Fai</creator><creator>Wong, Ian Chi Kei</creator><creator>Chan, Esther Wai Yin</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7T2</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7602-9470</orcidid></search><sort><creationdate>20240201</creationdate><title>Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study</title><author>Qin, Simon Xiwen ; Cheng, Franco Wing Tak ; Kwok, Wang Chun ; Fung, Lydia W. Y. ; Ma, Tian Tian ; Yiu, Hei Hang Edmund ; Bloom, Chloe ; McDonald, Christine F. ; Cheung, Ching-Lung ; Lai, Francisco Tsz Tsun ; Chui, Celine Sze Ling ; Li, Xue ; Wong, Carlos King Ho ; Wan, Eric Yuk Fai ; Wong, Ian Chi Kei ; Chan, Esther Wai Yin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-2546d7dd56b9ba01ae95146529c594afa6d7842e470edc9433008c7859c10943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Adverse events</topic><topic>Asthma</topic><topic>BNT162 Vaccine</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Cohort Studies</topic><topic>Complications</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Effectiveness</topic><topic>Electronic health records</topic><topic>Hong Kong - epidemiology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunization</topic><topic>Intensive care units</topic><topic>Lung diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>mRNA</topic><topic>Obstructive lung disease</topic><topic>Original</topic><topic>Original Research Article</topic><topic>Pharmacology/Toxicology</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Pulmonary Disease, Chronic Obstructive</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Statistical models</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qin, Simon Xiwen</creatorcontrib><creatorcontrib>Cheng, Franco Wing Tak</creatorcontrib><creatorcontrib>Kwok, Wang Chun</creatorcontrib><creatorcontrib>Fung, Lydia W. Y.</creatorcontrib><creatorcontrib>Ma, Tian Tian</creatorcontrib><creatorcontrib>Yiu, Hei Hang Edmund</creatorcontrib><creatorcontrib>Bloom, Chloe</creatorcontrib><creatorcontrib>McDonald, Christine F.</creatorcontrib><creatorcontrib>Cheung, Ching-Lung</creatorcontrib><creatorcontrib>Lai, Francisco Tsz Tsun</creatorcontrib><creatorcontrib>Chui, Celine Sze Ling</creatorcontrib><creatorcontrib>Li, Xue</creatorcontrib><creatorcontrib>Wong, Carlos King Ho</creatorcontrib><creatorcontrib>Wan, Eric Yuk Fai</creatorcontrib><creatorcontrib>Wong, Ian Chi Kei</creatorcontrib><creatorcontrib>Chan, Esther Wai Yin</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qin, Simon Xiwen</au><au>Cheng, Franco Wing Tak</au><au>Kwok, Wang Chun</au><au>Fung, Lydia W. Y.</au><au>Ma, Tian Tian</au><au>Yiu, Hei Hang Edmund</au><au>Bloom, Chloe</au><au>McDonald, Christine F.</au><au>Cheung, Ching-Lung</au><au>Lai, Francisco Tsz Tsun</au><au>Chui, Celine Sze Ling</au><au>Li, Xue</au><au>Wong, Carlos King Ho</au><au>Wan, Eric Yuk Fai</au><au>Wong, Ian Chi Kei</au><au>Chan, Esther Wai Yin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study</atitle><jtitle>Drug safety</jtitle><stitle>Drug Saf</stitle><addtitle>Drug Saf</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>47</volume><issue>2</issue><spage>135</spage><epage>146</epage><pages>135-146</pages><issn>0114-5916</issn><eissn>1179-1942</eissn><abstract>Introduction
Effectiveness and respiratory adverse events following coronavirus disease-2019 (COVID-19) vaccines have not been well investigated in Chinese patients with chronic obstructive pulmonary disease (COPD) and asthma.
Methods
Using electronic health care records in Hong Kong, we included adults with COPD or asthma or both and hospitalised for severe respiratory exacerbation in a self-controlled case series (SCCS) study between 23/02/2021 and 30/11/2022. Conditional Poisson regression models were used to estimate the incidence of outcomes within exposure periods (28 days after each dose) compared with baseline periods. Cox proportional hazard models evaluated vaccine effectiveness (VE) against COVID-related mortality, hospitalisation, and severe complications, including admission to intensive care units or ventilatory support. The VE assessment was based on vaccine types and the number of doses.
Results
In the SCCS, 343 CoronaVac recipients and 212 BNT162b2 recipients were included. No increased risk of outcomes was observed within the exposure periods. In the cohort study, 108,423 and 83,323 patients received ≥ 2 doses of CoronaVac and BNT162b2, respectively. The VE (95% CI) against COVID-related mortality, hospitalisation, and severe complications after two-dose CoronaVac was 77% (74–80%), 18% (6–23%), and 29% (12–43%), respectively, while for the two-dose regimen of BNT162b2, it was 92% (91–94%), 33% (30–37%), and 57% (45–66%), respectively. Higher VE against COVID-related mortality, hospitalisation, and severe complications was found for the three-dose regimen of CoronaVac (94%, 40%, and 71%) and BNT162b2 (98%, 65%, and 83%). Administering a fourth dose of either vaccine showed additional reductions in COVID-related outcomes.
Conclusions
Among people with COPD and asthma, the COVID-19 vaccines CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential and should be encouraged to protect this vulnerable population in future epidemic waves.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38085500</pmid><doi>10.1007/s40264-023-01364-7</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-7602-9470</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0114-5916 |
| ispartof | Drug safety, 2024-02, Vol.47 (2), p.135-146 |
| issn | 0114-5916 1179-1942 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10821837 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Adverse events Asthma BNT162 Vaccine Chronic obstructive pulmonary disease Cohort Studies Complications Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects Drug Safety and Pharmacovigilance Effectiveness Electronic health records Hong Kong - epidemiology Hospitals Humans Immunization Intensive care units Lung diseases Medicine Medicine & Public Health Mortality mRNA Obstructive lung disease Original Original Research Article Pharmacology/Toxicology Population studies Population-based studies Pulmonary Disease, Chronic Obstructive Regression analysis Regression models Statistical models Vaccine efficacy Vaccines Viral diseases |
| title | Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A58%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20Respiratory%20Adverse%20Events%20Following%20Inactivated%20and%20mRNA%20COVID-19%20Vaccines%20in%20Patients%20with%20COPD%20and%20Asthma:%20A%20Chinese%20Population-Based%20Study&rft.jtitle=Drug%20safety&rft.au=Qin,%20Simon%20Xiwen&rft.date=2024-02-01&rft.volume=47&rft.issue=2&rft.spage=135&rft.epage=146&rft.pages=135-146&rft.issn=0114-5916&rft.eissn=1179-1942&rft_id=info:doi/10.1007/s40264-023-01364-7&rft_dat=%3Cproquest_pubme%3E2919858504%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2919858504&rft_id=info:pmid/38085500&rfr_iscdi=true |